Avid Bioservices, Inc. (CDMOP) Stock Analysis

Avid Bioservices, Inc. (CDMOP) Healthcare & Pipeline Overview

Avid Bioservices, Inc. operates as a specialized contract development and manufacturing organization (CDMO) within the biopharmaceutical sector, focusing on mammalian cell culture for biologics production. It offers comprehensive process development and CGMP manufacturing services for monoclonal antibodies and recombinant proteins, supporting biotechnology and pharmaceutical clients from clinical to commercial stages.

What Is the Investment Thesis for CDMOP?

Avid Bioservices, Inc. operates as a specialized contract development and manufacturing organization (CDMO) with a core focus on mammalian cell culture for biopharmaceutical drug substances, including monoclonal antibodies and recombinant proteins. The investment thesis centers on the growing demand for outsourced biologics manufacturing, where Avid's established expertise in process development and CGMP-compliant clinical and commercial production serves as a key value driver. The company's comprehensive service offering, from upstream optimization to regulatory assistance, positions it to capture ongoing opportunities in a market increasingly reliant on specialized external partners. Growth catalysts include the continuous expansion of the global biologics market, which fuels the need for advanced manufacturing capabilities, and Avid's ability to secure new, long-term contracts. Strategic collaborations, such as the ongoing work with Oragenics, Inc. on a coronavirus vaccine, demonstrate potential for revenue diversification and market presence. However, the company faces an intensely competitive CDMO landscape and must effectively manage its production capacity and contract acquisition pipeline. Financially, Avid reported a Gross Margin of 5.2% and a Profit Margin of -100.6%, indicating operational challenges and a need for improved profitability, while its Beta of 2.70 suggests higher volatility relative to the broader market. Monitoring the company's success in converting its specialized capabilities into profitable contracts will be crucial.

Based on FMP financials and quantitative analysis

CDMOP Key Highlights

Gross Margin of 5.2% reflects the company's profitability after accounting for the cost of goods sold.

• Profit Margin of -100.6% indicates the company is currently operating at a net loss relative to its revenue.
• Beta of 2.70 suggests higher volatility compared to the overall market, indicating greater price swings.
• Specialization in mammalian cell culture for biopharmaceutical drug substances, including monoclonal antibodies and recombinant proteins.
• Offers comprehensive CDMO services covering process development, CGMP clinical and commercial manufacturing, and regulatory assistance.

Who Are CDMOP's Competitors?

CDMOP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CDMOP's Key Strengths?

Established expertise in mammalian cell culture for biopharmaceutical drug substances.

• Comprehensive CDMO services covering process development and CGMP manufacturing.
• Adherence to current Good Manufacturing Practices (CGMP) for clinical and commercial production.
• Collaboration with Oragenics, Inc. on coronavirus vaccine development.

What Are CDMOP's Weaknesses?

Negative Profit Margin of -100.6% indicates current unprofitability.

• Low Gross Margin of 5.2% suggests limited profitability from core operations.
• High Beta of 2.70 implies significant stock price volatility.
• Reliance on securing new contracts in a competitive industry.

What Could Drive CDMOP Stock Higher?

Continued expansion of the global biologics market driving sustained demand for specialized CDMO services.

• Securing new contract development and manufacturing agreements with biotechnology and pharmaceutical clients, enhancing revenue streams.
• Progress and potential commercialization of the coronavirus vaccine collaboration with Oragenics, Inc., offering future revenue opportunities.

What Are the Key Risks for CDMOP?

Intense competition within the contract development and manufacturing organization (CDMO) industry, potentially impacting pricing and market share.

• Challenges in securing new contracts and maintaining a robust client pipeline, which could affect revenue growth.
• Managing production capacity effectively to meet client demands and optimize operational efficiency, with risks of underutilization or overextension.
• Fluctuations in client R&D spending and drug development timelines, impacting demand for Avid's services and project continuity.

What Are the Growth Opportunities for CDMOP?

• Expanding Biologics Manufacturing Capacity: The global biologics market continues to expand significantly, projected to reach substantial market sizes in the coming years, driven by the increasing prevalence of chronic diseases and the development of novel therapies. Avid Bioservices, with its specialized mammalian cell culture capabilities for producing monoclonal antibodies and recombinant proteins, is strategically positioned to capitalize on this sustained growth. The rising demand for outsourced manufacturing services, particularly for complex biologics requiring stringent quality controls and specialized expertise, presents Avid with opportunities to secure larger and more numerous contracts. This growth driver is ongoing, as biopharmaceutical pipelines globally remain robust, necessitating reliable and expert CDMO partners for successful drug development and commercialization. Avid's established expertise and CGMP compliance offer a competitive advantage in attracting clients seeking high-quality production.
• Strategic Collaborations and Partnerships: The company's collaboration with Oragenics, Inc. for a coronavirus vaccine exemplifies a significant growth pathway through strategic partnerships. Such agreements can lead to substantial, long-term revenue streams and significantly enhance Avid's reputation and market visibility in specific therapeutic areas, potentially opening doors to new client segments. As pharmaceutical and biotechnology companies increasingly seek external partners for specialized development and manufacturing capabilities, Avid can actively pursue similar collaborations across various therapeutic modalities or drug classes. These partnerships often involve multi-year contracts, providing a degree of revenue predictability and stability, which is valuable in the often-volatile biopharmaceutical sector.
• Process Development and Optimization Services: Avid's comprehensive suite of process development services, which includes upstream and downstream optimization, alongside analytical method development and characterization, represents a critical value proposition for its clientele. As drug candidates progress through various clinical stages, optimizing manufacturing processes becomes paramount for achieving scalability, reducing costs, and ensuring product consistency and quality. Avid's deep expertise in these intricate areas can attract both nascent biotechnology firms and larger pharmaceutical companies aiming to streamline their drug development pipelines and accelerate time-to-market. This service segment experiences ongoing demand, as virtually every new drug entity requires tailored process solutions to transition from laboratory to commercial viability efficiently.
• Regulatory Support and Compliance Expertise: The biopharmaceutical industry operates under a stringent regulatory framework, making navigation of current Good Manufacturing Practices (CGMP) and various regulatory approval processes a significant challenge for many companies. Avid Bioservices offers vital regulatory submission and assistance services, which can serve as a key differentiator in a competitive market. By providing robust support for regulatory filings, ensuring continuous compliance throughout the manufacturing lifecycle, and leveraging its experience with regulatory bodies, Avid significantly reduces the operational and compliance burden on its clients. This specialized expertise is consistently in demand and can attract clients who prioritize a CDMO partner with a proven track record in regulatory adherence, particularly for complex biologics.
• Diversification into Emerging Biologic Modalities: While Avid Bioservices currently specializes in monoclonal antibodies and recombinant proteins via mammalian cell culture, the broader biologics market is rapidly evolving to include emerging modalities such as gene therapies, cell therapies, and viral vectors. Although the provided data specifically highlights mammalian cell culture and viral vector production, expanding capabilities or forming strategic alliances to address these rapidly growing segments could represent a significant future growth avenue. This strategic diversification would enable Avid to tap into new, high-growth areas of the biopharmaceutical market, broaden its service portfolio, and attract a more diverse client base over the medium to long term, enhancing its competitive position.

What Are CDMOP's Competitive Advantages?

• Specialized expertise in mammalian cell culture for complex biopharmaceutical drug substances, a high-barrier-to-entry field.
• Comprehensive service offering spanning process development to CGMP commercial manufacturing, providing an integrated solution.
• Established track record and adherence to current Good Manufacturing Practices (CGMP), ensuring high quality and regulatory compliance.
• Provision of regulatory submission and assistance capabilities, which reduces the burden and risk for clients navigating complex approval processes.

What Does CDMOP Do?

Avid Bioservices, Inc., founded in 1981, initially operated as Peregrine Pharmaceuticals, Inc. before rebranding to its current name in January 2018. Headquartered in Tustin, California, the company functions as a specialized contract development and manufacturing organization (CDMO) primarily focused on the biopharmaceutical sector. Its core expertise lies in the production of drug substances through mammalian cell culture, a critical process for developing complex biologics. Avid Bioservices excels in manufacturing vital biologics, including monoclonal antibodies and recombinant proteins, which are essential components in many modern therapeutic treatments. The company's service portfolio is comprehensive, covering both the early stages of process development and full-scale commercial manufacturing. In process development, Avid Bioservices offers upstream and downstream optimization, crucial for enhancing yield and purity, alongside the creation, testing, and characterization of analytical methods to ensure product quality and consistency. For manufacturing, the company adheres strictly to current Good Manufacturing Practices (CGMP), providing clinical and commercial production capabilities. These services encompass purification, bulk packaging, rigorous release and stability testing, and essential regulatory submission and assistance, guiding clients through complex approval processes. Avid Bioservices serves a diverse clientele within the biotechnology and pharmaceutical sectors, supporting them from preclinical development through to commercialization. A notable collaboration includes a process development and manufacturing agreement with Oragenics, Inc. for the development of a coronavirus vaccine, highlighting its involvement in critical public health initiatives. With 222 employees, Avid Bioservices maintains a focused operational footprint, leveraging its specialized capabilities to address the intricate demands of biopharmaceutical drug substance production. Its evolution from Peregrine Pharmaceuticals reflects a strategic pivot to concentrate on its CDMO strengths, positioning it as a key partner in the biopharmaceutical supply chain.

What Products and Services Does CDMOP Offer?

• Operates as a Contract Development and Manufacturing Organization (CDMO) for biopharmaceuticals.
• Specializes in producing drug substances using mammalian cell culture techniques.
• Manufactures crucial biologics, including monoclonal antibodies and recombinant proteins.
• Offers comprehensive process development services, such as upstream and downstream optimization.
• Provides analytical method creation, testing, and characterization to ensure product quality.
• Conducts full current Good Manufacturing Practices (CGMP) compliant clinical manufacturing.
• Performs commercial manufacturing services, including purification and bulk packaging.
• Assists clients with vital regulatory submissions and provides ongoing regulatory support.

How Does CDMOP Make Money?

• Generates revenue by providing contract development and manufacturing services to biotechnology and pharmaceutical companies.
• Charges fees for specialized process development, optimization, and analytical method services.
• Earns income from CGMP-compliant clinical and commercial manufacturing of biologics.
• Provides value-added services such as purification, bulk packaging, release/stability testing, and regulatory assistance on a contractual basis.

What Industry Does CDMOP Operate In?

Avid Bioservices, Inc. operates within the highly specialized and competitive biotechnology industry, specifically as a contract development and manufacturing organization (CDMO) focused on biopharmaceutical drug substances. The broader healthcare sector is experiencing robust growth in biologics, driven by advancements in therapeutic areas like oncology, autoimmune diseases, and infectious diseases. This trend fuels the demand for outsourced manufacturing, as many biotechnology and pharmaceutical companies seek specialized expertise, advanced facilities, and cost efficiencies that CDMOs like Avid can provide. The global CDMO market for biologics is expanding, with significant investments in mammalian cell culture capabilities, which is Avid's core strength. Avid's competitive landscape includes larger, diversified CDMOs and smaller, niche players. Its positioning is defined by its specialization in mammalian cell culture for monoclonal antibodies and recombinant proteins, offering a comprehensive suite of services from process development to CGMP commercial manufacturing. While the market offers substantial opportunities, the intensity of competition necessitates continuous innovation, efficient operations, and strong client relationships. Avid's ability to secure new contracts and manage its production capacity effectively will be critical for its sustained growth in this dynamic environment.

Who Are CDMOP's Key Customers?

• Biotechnology companies developing novel biologic therapies.
• Pharmaceutical companies requiring outsourced manufacturing for their drug pipelines.
• Companies engaged in vaccine development, such as Oragenics, Inc.
• Clients seeking specialized expertise in mammalian cell culture and biologics production for clinical and commercial needs.

Company Profile

Avid Bioservices, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Tustin, US. The company is led by CEO Richard B. Hancock. CDMOP has traded publicly since 2014.

Key Financial Metrics

Return on assets is -41.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.47 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -17.8%, the inverse of the P/E and a quick read on earnings relative to price.

CDMOP Financials

CDMOP Latest News

No recent news available for CDMOP.

What Investors Ask About Avid Bioservices, Inc. (CDMOP) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources